Treatment of a condition characterized by unwanted choroidal neovascularization is described using a combination of photodynamic therapy and an anti-VEFG agent. These conditions include age-related macular degeneration. Preferred anti-VEGF agents include antibodies such as bevacizumab or ranibizumab. The photosensitizer can be selected from green porphyrins such as BPD-MA (berteppin) and can achieve photodynamic activation of the photosensitizer with low fluence. Additional anti-inflammatory agents such as dexamethasone may also be used.
展开▼
